Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sandoz’s Binocrit approved for subcutaneous administration

Sandoz’s Binocrit approved for subcutaneous administration

8th April 2016

Sandoz has announced that its drug Binocrit has been approved in Europe for subcutaneous administration.

The European Commission has approved a type II variation for the addition of a subcutaneous route of administration in Binocrit's nephrology indication, based on positive data from the clinical study SENSE.

This trial demonstrated the safety and immunogenicity of the HX575 epoetin alfa therapy in the treatment of anaemia associated with chronic kidney disease in predialysis and dialysis patients.

Since its release, Binocrit has generated more than 400,000 patient years of experience worldwide.

Carol Lynch, global head for biopharmaceuticals at Sandoz, said: "The European Commission approval of a subcutaneous route of administration for use in our Binocrit's nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients."

Binocrit is a prescription medicine that works by stimulating the bone marrow to produce red blood cells.ADNFCR-8000103-ID-801816261-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.